What are the clinicians prompted by?

Professor Paul Zimmet (MD, Ph.D., honorary director of the Baker IDI heart and Diabetes Institute, Melbourne, Australia, Monash University Professor, University of Pittsburgh, Pennsylvania, USA Professor) , during an interview, said the study was partially copied the studies of he and his team published 20 years ago and the results other studies have shown.

In the entire study population, the prevalence of LADA is three times larger than the prevalence of autoimmune type 1 diabetes (377 patients vs 114 patients), the odds ratio was 3.3. Other analysis showed that compared with patients of GADA with lower levels, patients of high GADA titer and type 1 diabetes are more similar (younger, leaner, treated with insulin, etc.), but in a variety of the GADA titer we can see in the scope of each type of autoimmune diabetes. Hawa and colleagues point out.

"This is a very large research, but in fact it only confirm a lot of information about the LADA published by other scholars in the past 20 years. Positive side is that this study provide further important reminder for clinicians, including primary care physicians: You must realize that LADA is a high prevalence of the disease, especially in the European population." Dr. Zimmet (co-Leader of Epidemiology and Prevention Working Group of the International Diabetes Federation (IDF) ) said in an interview.

He said antibody testing fee for all adult-onset diabetes and clinical benefits are not high, but the detection of GADA in healthy adults is meaningful, especially in those of European descent and obese patients with type 2 diabetes failed in the conventional therapy. Dr. Zimmet realized that this possibility is the key.

recombinant cytokines

Bone Morphogenetic Protein 2

M-CSF